FDA approves Rasonque for advanced pancreatic cancer

When patients with advanced pancreatic cancer received Revolution Medicines’ Rasonque as a second-line treatment, the median overall survival reached 13.2 months. Patients offered standard chemotherapy reached 6.7 months. The comparison is the central fact behind the FDA’s approval of the drug, which is sold under the brand name Rasonque and is also called daraxonrasib.

The treatment targets a genetic cause of pancreatic cancer, making it the first approved medicine described as attacking that cause. The source does not provide a fuller account of how the drug works inside cancer cells, but it places the therapy against a disease described as aggressive and highly lethal.

The numbers come from a clinical trial that read out earlier in 2026 and supported the FDA decision. They are median figures: half the patients lived longer and half lived less than the stated time. No price, treatment duration, or independent real-world assessment is provided in the report, so the trial result should not be read as a guarantee for every patient.

For patients and oncologists, the practical change is immediate but specific: people with advanced pancreatic cancer who reach the second-line stage now have an FDA-approved option associated with nearly twice the median overall survival seen with standard chemotherapy in the trial. Andrew Ko, a gastrointestinal cancer specialist at the University of California, San Francisco, said the result could transform treatment and called it the biggest development in pancreatic cancer in decades.

The approval matters because it turns a treatment aimed at a genetic driver into an available clinical option, not merely a laboratory idea. Its limits are equally clear: the evidence described here comes from one clinical trial, and the report does not establish how the benefit will hold up across routine care or how patients will respond over longer follow-up.